Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Earl Martin

Family Medicine Tomball, TX Medical Doctor

NPI 1013998384 CMS profile 227897

710 Lawrence St, Tomball, TX 77375

Open in the dashboard

General payments

$3,354

211 records reported · program years 2019–2025

Research payments

$88,568

Paid to them · 15 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$30,089,765 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Earl Martin of Tomball, TX is reported in the CMS Open Payments database as having received $3,354 across 211 general payments and $88,568 in research payments paid to them. Separately, studies naming them as principal investigator received $30,089,765 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $109 5
2024 General $182 9
2023 General $271 15
2022 General $425 27
2022 Research $85,726 12
2021 General $1,058 65
2020 General $824 59
2019 General $486 31
2019 Research $2,842 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Earl Martin
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Earl Martin were reported at $109. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Earl Martin Family Medicine median Middle half National median
2019 $486 $150 $41–$543 $163
2020 $824 $120 $32–$415 $114
2021 $1,058 $137 $35–$551 $132
2022 $425 $137 $37–$512 $149
2023 $271 $149 $42–$545 $160
2024 $182 $156 $44–$560 $164
2025 $109 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $488 31 payments
  2. Novo Nordisk Inc $412 26 payments
  3. Novartis Pharmaceuticals Corporation $240 14 payments
  4. Hikma Pharmaceuticals USA $210 11 payments
  5. AbbVie, Inc. $206 11 payments
  6. Lilly USA, LLC $198 12 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $146 7 payments
  8. AstraZeneca Pharmaceuticals LP $143 10 payments
  9. GlaxoSmithKline, LLC. $138 8 payments
  10. Aytu BioScience, Inc $128 17 payments
  11. Other $1,046 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,307 207 payments
  2. Education $27 3 payments
  3. Gift $20 1 payment
Products named General payments · program years 2019–2025
  1. Repatha $382 24 payments
  2. Ozempic $381 24 payments
  3. RYBELSUS $368 23 payments
  4. AIMOVIG $285 19 payments
  5. Mitigare $210 11 payments
  6. Otezla $186 10 payments
  7. TRULICITY $165 10 payments
  8. ENTRESTO $147 9 payments
  9. JARDIANCE $136 8 payments
  10. Natesto $128 17 payments
  11. Other $2,461 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Valneva Austria GmbH $85,396 11 payments
  2. Eli Lilly and Company $2,842 3 payments
  3. Pfizer Inc. $330 1 payment

Records

226 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record